REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2023.
Recent Highlights
“In 2023, our customers continued to demonstrate the powerful biological insight that is uniquely possible by leveraging the Proteograph Product Suite. Recently, we saw our first customer study published in Nature Communications and we expect several more this year,” said Omid Farokhzad, Chair and CEO. “Looking ahead, we are laser focused on translating the incredible performance of our platform and the uniqueness of the data it generates into widespread commercial adoption. I continue to be confident in the substantial long-term opportunity ahead and look forward to updating on our progress throughout 2024.”
Fourth Quarter 2023 Financial Results
Revenue was $4.4 million for the three months ended December 31, 2023, a 3.6% decrease from $4.6 million for the three months ended December 31, 2022. This decrease was primarily due to a decrease in lease revenue related to SP100 instruments, partially offset by an increase in service revenue. Product revenue for the fourth quarter of 2023 was $3.0 million, including $366 thousand of related party revenue, and consisted of sales of SP100 instruments and consumable kits. Service revenue was $1.1 million, including $201 thousand of related party revenue, and primarily consisted of revenue related to the Seer Technology Access Center, and grant and other revenue was $258 thousand.
Gross profit, inclusive of grant and other revenue, was $2.0 million and gross margin was 45.1% for the fourth quarter of 2023.
Operating expenses were $24.2 million for the fourth quarter of 2023, including $7.6 million of stock-based compensation, a decrease of 11% as compared to $27.2 million, including $8.2 million of stock-based compensation, for the corresponding prior year period. The decrease in expenses was primarily driven by a decrease in product development costs related to the Proteograph Product Suite, including employee compensation and other related expenses.
Net loss was $17.8 million for the fourth quarter of 2023, as compared to $22.5 million for the corresponding prior year period.
Full Year 2023 Financial Results
Revenue was $16.7 million for the year ended December 31, 2023, an 8% increase from $15.5 million for the year ended December 31, 2022. Product revenue for the full year 2023 was $12.9 million, including $4.4 million of related party revenue. Service revenue was $2.3 million, including $241 thousand of related party revenue, and grant and other revenue was $1.5 million.
Gross profit, inclusive of grant and other revenue, was $8.5 million and gross margin was 51.1% for the full year 2023.
Operating expenses were $112.0 million for the full year 2023, including $34.4 million of stock-based compensation, as compared to $104.3 million, including $33.7 million of stock-based compensation, for the corresponding prior year period.
Net loss was $86.3 million for the full year 2023, as compared to $93.0 million for the corresponding prior year period.
Cash, cash equivalents and investments were $373.1 million as of December 31, 2023.
2024 Guidance
Seer expects full year 2024 revenue to be in the range of $18 million to $20 million, representing growth of 14% at the midpoint over full year 2023.
Webcast Information
Seer will host a conference call to discuss the fourth quarter and full year 2023 financial results on Thursday, February 29, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at http://investor.seer.bio. The webcast will be archived and available for replay for at least 90 days after the event.
About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the Company’s expectations for future results of operations and its financial position, business strategy, customer publications and adoption and outlook for fiscal year 2024. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Carrie Mendivil
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Patrick Schmidt
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Seer, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) | |||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||
| Revenue: | |||||||||||||||||||
| Product | $ | 2,669 | $ | 1,431 | $ | 8,506 | $ | 8,557 | |||||||||||
| Service | 944 | 708 | 2,016 | 913 | |||||||||||||||
| Related party | 567 | 1,720 | 4,660 | 5,215 | |||||||||||||||
| Grant and other | 258 | 745 | 1,479 | 808 | |||||||||||||||
| Total revenue | 4,438 | 4,604 | 16,661 | 15,493 | |||||||||||||||
| Cost of revenue: | |||||||||||||||||||
| Product | 1,663 | 785 | 5,398 | 5,459 | |||||||||||||||
| Service | 390 | 446 | 685 | 495 | |||||||||||||||
| Related party | 204 | 624 | 1,430 | 1,989 | |||||||||||||||
| Grant and other | 180 | 457 | 642 | 457 | |||||||||||||||
| Total cost of revenue | 2,437 | 2,312 | 8,155 | 8,400 | |||||||||||||||
| Gross profit | 2,001 | 2,292 | 8,506 | 7,093 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||
| Research and development | 11,165 | 12,631 | 53,019 | 45,797 | |||||||||||||||
| Selling, general and administrative | 13,068 | 14,612 | 58,950 | 58,531 | |||||||||||||||
| Total operating expenses | 24,233 | 27,243 | 111,969 | 104,328 | |||||||||||||||
| Loss from operations | (22,232 | ) | (24,951 | ) | (103,463 | ) | (97,235 | ) | |||||||||||
| Other income (expense): | |||||||||||||||||||
| Interest income | 4,720 | 2,498 | 17,764 | 4,602 | |||||||||||||||
| Other expense | (287 | ) | (73 | ) | (578 | ) | (333 | ) | |||||||||||
| Total other income | 4,433 | 2,425 | 17,186 | 4,269 | |||||||||||||||
| Net loss | $ | (17,799 | ) | $ | (22,526 | ) | $ | (86,277 | ) | $ | (92,966 | ) | |||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.28 | ) | $ | (0.36 | ) | $ | (1.35 | ) | $ | (1.49 | ) | |||||||
| Weighted-average common shares outstanding, basic and diluted | 64,157,125 | 62,805,423 | 63,850,490 | 62,433,613 | |||||||||||||||
| Seer, Inc. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share amounts) | |||||||
| December 31, | |||||||
| 2023 | 2022 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 32,499 | $ | 53,208 | |||
| Short-term investments | 283,725 | 368,031 | |||||
| Accounts receivable, net | 4,831 | 4,315 | |||||
| Related party receivables | 559 | 1,804 | |||||
| Other receivables | 1,326 | 899 | |||||
| Inventory | 4,491 | 4,627 | |||||
| Prepaid expenses and other current assets | 3,082 | 2,098 | |||||
| Total current assets | 330,513 | 434,982 | |||||
| Long-term investments | 56,858 | 5,157 | |||||
| Operating lease right-of-use assets | 25,177 | 27,003 | |||||
| Property and equipment, net | 22,193 | 19,408 | |||||
| Restricted cash | 524 | 524 | |||||
| Other assets | 1,004 | 855 | |||||
| Total assets | $ | 436,269 | $ | 487,929 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,370 | $ | 2,104 | |||
| Accrued expenses | 9,212 | 8,298 | |||||
| Deferred revenue | 206 | 133 | |||||
| Operating lease liabilities, current | 2,295 | 1,842 | |||||
| Other current liabilities | 139 | 207 | |||||
| Total current liabilities | 13,222 | 12,584 | |||||
| Operating lease liabilities, net of current portion | 25,964 | 28,032 | |||||
| Other noncurrent liabilities | 179 | 320 | |||||
| Total liabilities | 39,365 | 40,936 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.00001 par value; 5,000,000 shares authorized as of December 31, 2023 and 2022; zero shares issued and outstanding as of December 31, 2023 and 2022 | — | — | |||||
| Class A common stock, $0.00001 par value; 94,000,000 shares authorized as of December 31, 2023 and 2022; 60,253,707 and 59,366,077 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 1 | 1 | |||||
| Class B common stock, $0.00001 par value; 6,000,000 shares authorized as of December 31, 2023 and 2022; 4,044,969 shares issued and outstanding as of December 31, 2023 and 2022 | — | — | |||||
| Additional paid-in capital | 702,868 | 667,739 | |||||
| Accumulated other comprehensive loss | (192 | ) | (1,251 | ) | |||
| Accumulated deficit | (305,773 | ) | (219,496 | ) | |||
| Total stockholders’ equity | 396,904 | 446,993 | |||||
| Total liabilities and stockholders’ equity | $ | 436,269 | $ | 487,929 | |||
| Last Trade: | US$2.50 |
| Daily Change: | -0.03 -1.19 |
| Daily Volume: | 33,597 |
| Market Cap: | US$137.300M |
November 06, 2024 October 31, 2024 October 21, 2024 August 08, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
